Youkyung Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Youkyung Lim has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Harmen J. G. van de Werken
Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Immunology, Rotterdam, The Netherlands
15 shared publications - Christopher Schliehe
Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
14 shared publications - Dwin G. B. Grashof
Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands
14 shared publications - Peter D. Katsikis
Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
14 shared publications - Anneloes van Krimpen
Department of Pulmonary Medicine, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
13 shared publications - Brett J. Hos
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands
13 shared publications
Latest Publications
- Open Access
Prime-Target neoantigen vaccination unleashes unprecedented T cell immunity within “cold” immunosuppressive tumors
“Cold” immunosuppressive solid tumors are hard-to-treat cancers that are non-responsive to immunotherapies. Their immunosuppressive tumor microenvironment (TME) excludes and inhibits T cells and thereby hampers the therapeutic efficacy of cancer vaccines and immune checkpoint blockade. To overcome this, we employed a “Prime-Target” (P/T) neoantigen vaccination strategy that combines subcutaneous (SQ) and intra-tumor (IT) neopeptide vaccinations to first prime potent systemic neoantigen-specific T cell immunity and then trigger intratumoral T cell recruitment. Using immunotherapy non-responsive murine tumor models with pronounced immunosuppressive TMEs, we demonstrate that P/T neopeptide vaccination resulted in extraordinary tumor control and TME remodeling. P/T vaccination elicited strong systemic anti-tumor responses as well as potent and rapid recruitment of clonal CD4 + Th1 and non-exhausted CD8 + T cells into tumors that carried novel T cell receptors (TCR) and were vaccine neopeptide-specific. Concurrently, P/T vaccination reshaped the TME by decreasing suppressive Treg and M2 macrophages, and dramatically increasing the ratio of effector T cells to Treg and M2 macrophages. Vaccination-induced tumor control was neopeptide-dependent and required concurrent IT administration of both neopeptides and adjuvants. Our study highlights P/T neoantigen vaccination as a promising strategy to overcome T cell exclusion within “cold” immunosuppressive solid tumors and thereby unleash unprecedented anti-tumor immunity.
Open AccessPrime-Target neoantigen vaccination unleashes unprecedented T cell immunity within “cold” immunosuppressive tumors
“Cold” immunosuppressive solid tumors are hard-to-treat cancers that are non-responsive to immunotherapies. Their immunosuppressive tumor microenvironment (TME) excludes and inhibits T cells and thereby hampers the therapeutic efficacy of cancer vaccines and immune checkpoint blockade. To overcome this, we employed a “Prime-Target” (P/T) neoantigen vaccination strategy that combines subcutaneous (SQ) and intra-tumor (IT) neopeptide vaccinations to first prime potent systemic neoantigen-specific T cell immunity and then trigger intratumoral T cell recruitment. Using immunotherapy non-responsive murine tumor models with pronounced immunosuppressive TMEs, we demonstrate that P/T neopeptide vaccination resulted in extraordinary tumor control and TME remodeling. P/T vaccination elicited strong systemic anti-tumor responses as well as potent and rapid recruitment of clonal CD4 + Th1 and non-exhausted CD8 + T cells into tumors that carried novel T cell receptors (TCR) and were vaccine neopeptide-specific. Concurrently, P/T vaccination reshaped the TME by decreasing suppressive Treg and M2 macrophages, and dramatically increasing the ratio of effector T cells to Treg and M2 macrophages. Vaccination-induced tumor control was neopeptide-dependent and required concurrent IT administration of both neopeptides and adjuvants. Our study highlights P/T neoantigen vaccination as a promising strategy to overcome T cell exclusion within “cold” immunosuppressive solid tumors and thereby unleash unprecedented anti-tumor immunity.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 1 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 1 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 2 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 2 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 4 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 4 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 3 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice
Supplementary Table 3 from CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice